Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

6 of 6
BACK NEXT
Genentech
Genentech
Debt as a % of capital: 16%
Return on capital: 23%

The biotech business is all about what new products are coming down the pipeline. So, like most drugmakers, Genentech uses its cash to fund research and development.

And San Francisco-based company, which discovers and develops a wide range of pharmaceutical products, has emerged as one of the industry's leaders.

"Genentech has the broadest clinical pipeline in the biotechnology industry," according to a recent research report by JPMorgan analyst Geoffrey Meacham.

What's more, Genentech has a successful track record for using its cash to fund research in areas that other drugmakers may have overlooked.

"Historically, the company has been effective in focusing its resources in areas of significant unmet medical need, and hence blockbuster sales potential," Meacham wrote.

The company has been particularly adept at finding new cancer treatments, says analyst Eric Schmidt of Cowen and Company. And that's a big reason why analysts expect Genentech's earnings to increase at about a 23% clip a year, on average, for the next few years.

More galleries

Last updated June 20 2008: 1:08 PM ET
More Galleries
Here's what costs more than a barrel of oil Oil prices have crashed to below $27 a gallon -- a level not seen since 2003 -- which makes a barrel of crude cheaper than lots of everyday purchases that we don't think twice about. More
Super Bowl 50 ads are studded with celebrities The 2016 Super Bowl has rolled out the red carpet for the likes of Helen Mirren, Amy Schumer, Seth Rogen, Steven Tyler and the late, great Marilyn Monroe. More
The women of marijuana These women entrepreneurs and executives are making their mark in the marijuana industry. More

Special Offer